Progyny [PGNY] vs CVS Health [CVS] Detailed Stock Comparison
Progyny
NASDAQ
Loading...
CVS Health
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Progyny wins in 8 metrics, CVS Health wins in 11 metrics, with 0 ties. CVS Health appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Progyny | CVS Health | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 38.54 | 19.11 | CVS Health |
| Price-to-Book Ratio | 3.77 | 1.12 | CVS Health |
| Debt-to-Equity Ratio | 5.56 | 106.67 | Progyny |
| PEG Ratio | 3.47 | 10.59 | Progyny |
| EV/EBITDA | 20.78 | 11.15 | CVS Health |
| Profit Margin (TTM) | 4.28% | 1.18% | Progyny |
| Operating Margin (TTM) | 7.32% | 2.80% | Progyny |
| EBITDA Margin (TTM) | 7.32% | 2.80% | Progyny |
| Return on Equity | 10.94% | 5.88% | Progyny |
| Return on Assets (TTM) | 6.57% | 2.29% | Progyny |
| Free Cash Flow (TTM) | $173.70M | $6.33B | CVS Health |
| Dividend Yield | N/A | 3.01% | N/A |
| 1-Year Return | 6.10% | 21.58% | CVS Health |
| Price-to-Sales Ratio (TTM) | 1.57 | 0.23 | CVS Health |
| Enterprise Value | $1.68B | $155.73B | CVS Health |
| EV/Revenue Ratio | 1.35 | 0.41 | CVS Health |
| Gross Profit Margin (TTM) | 23.72% | 13.74% | Progyny |
| Revenue per Share (TTM) | $14 | $305 | CVS Health |
| Earnings per Share (Diluted) | $0.59 | $3.59 | CVS Health |
| Beta (Stock Volatility) | 1.33 | 0.59 | CVS Health |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Progyny vs CVS Health Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Progyny | 2.53% | 2.57% | 0.83% | 9.16% | -0.30% | 30.46% |
| CVS Health | 0.86% | 7.04% | 15.88% | 15.01% | 12.52% | 61.53% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Progyny | 6.10% | -44.49% | -19.10% | 45.11% | 45.11% | 45.11% |
| CVS Health | 21.58% | -28.61% | 13.00% | -31.44% | 159.65% | 146.48% |
Performance & Financial Health Analysis: Progyny vs CVS Health
| Metric | PGNY | CVS |
|---|---|---|
| Market Information | ||
| Market Cap | $1.96B | $87.01B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,385,600 | 6,343,070 |
| 90 Day Avg. Volume | 1,083,093 | 8,167,500 |
| Last Close | $23.13 | $71.43 |
| 52 Week Range | $13.39 - $26.76 | $43.56 - $72.51 |
| % from 52W High | -13.57% | -1.49% |
| All-Time High | $68.32 (Nov 01, 2021) | $113.65 (Jul 27, 2015) |
| % from All-Time High | -66.14% | -37.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.08% |
| Quarterly Earnings Growth | 0.04% | -0.42% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.01% |
| Operating Margin (TTM) | 0.07% | 0.03% |
| Return on Equity (TTM) | 0.11% | 0.06% |
| Debt to Equity (MRQ) | 5.56 | 106.67 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.04 | $61.07 |
| Cash per Share (MRQ) | $3.55 | $11.18 |
| Operating Cash Flow (TTM) | $202.00M | $7.57B |
| Levered Free Cash Flow (TTM) | $194.61M | $5.83B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 3.01% |
| Last 12-Month Dividend | N/A | $2.01 |
Valuation & Enterprise Metrics Analysis: Progyny vs CVS Health
| Metric | PGNY | CVS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 38.54 | 19.11 |
| Forward P/E | 29.92 | 10.59 |
| PEG Ratio | 3.47 | 10.59 |
| Price to Sales (TTM) | 1.57 | 0.23 |
| Price to Book (MRQ) | 3.77 | 1.12 |
| Market Capitalization | ||
| Market Capitalization | $1.96B | $87.01B |
| Enterprise Value | $1.68B | $155.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.35 | 0.41 |
| Enterprise to EBITDA | 20.78 | 11.15 |
| Risk & Other Metrics | ||
| Beta | 1.33 | 0.59 |
| Book Value per Share (MRQ) | $6.04 | $61.07 |
Financial Statements Comparison: Progyny vs CVS Health
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PGNY | CVS |
|---|---|---|
| Revenue/Sales | $332.87M | $94.59B |
| Cost of Goods Sold | $253.90M | $80.19B |
| Gross Profit | $78.97M | $14.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $24.36M | $3.37B |
| EBITDA | $25.56M | $4.56B |
| Pre-Tax Income | $27.08M | $2.62B |
| Income Tax | $9.97M | $835.00M |
| Net Income (Profit) | $17.11M | $1.78B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PGNY | CVS |
|---|---|---|
| Cash & Equivalents | $109.24M | $10.08B |
| Total Current Assets | $567.69M | $73.19B |
| Total Current Liabilities | $237.13M | $88.96B |
| Long-Term Debt | $26.00M | $73.63B |
| Total Shareholders Equity | $467.16M | $77.11B |
| Retained Earnings | $159.37M | $63.77B |
| Property, Plant & Equipment | $42.69M | $28.56B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PGNY | CVS |
|---|---|---|
| Operating Cash Flow | $27.84M | $3.96B |
| Capital Expenditures | $-2.84M | $-743.00M |
| Free Cash Flow | $46.97M | $3.81B |
| Debt Repayment | N/A | $-743.00M |
| Common Stock Repurchase | $0 | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | PGNY | CVS |
|---|---|---|
| Shares Short | 7.76M | 15.65M |
| Short Ratio | 7.47 | 1.83 |
| Short % of Float | 0.12% | 0.01% |
| Average Daily Volume (10 Day) | 1,385,600 | 6,343,070 |
| Average Daily Volume (90 Day) | 1,083,093 | 8,167,500 |
| Shares Outstanding | 85.31M | 1.26B |
| Float Shares | 79.61M | 1.27B |
| % Held by Insiders | 0.08% | 0.01% |
| % Held by Institutions | 1.04% | 0.88% |
Dividend Analysis & Yield Comparison: Progyny vs CVS Health
| Metric | PGNY | CVS |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.01 |
| Last 12-Month Dividend Yield | N/A | 3.01% |
| 3-Year Avg Annual Dividend | N/A | $2.28 |
| 3-Year Avg Dividend Yield | N/A | 0.87% |
| 3-Year Total Dividends | N/A | $6.85 |
| Ex-Dividend Date | N/A | Apr 22, 2025 |